Lanreotide vs Octreotide

	Lanreotide FDA Approved	Octreotide FDA Approved
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong	5/5 Very strong Evidence rating 5 out of 5: Very strong
Regulatory status	FDA-approved 2007 for acromegaly, 2014 for gastroenteropancreatic neuroendocrine tumours, and 2017 for carcinoid syndrome. The first generic entered the US market in 2021.	FDA-approved 1988 for acromegaly and for the diarrhoea of carcinoid and VIPoma tumours. An oral delayed-release capsule was approved in 2020 for maintenance in acromegaly.
Category	Hormonal & Reproductive	Hormonal & Reproductive
Drug class	Synthetic cyclic octapeptide somatostatin analogue, disulfide-bridged and D-amino acid substituted; formulated as a supersaturated aqueous gel that self-assembles into a depot without a polymer carrier	Synthetic cyclic octapeptide analogue of somatostatin, cyclised by a disulfide bridge and built with D-amino acids that resist enzymatic breakdown
Route	Deep subcutaneous injection every 4 weeks; intervals of 6–8 weeks are used in well-controlled patients	Subcutaneous injection, intramuscular depot every 4 weeks, intravenous infusion, or delayed-release oral capsule
Half-life	Around 23–30 days from the gel depot	About 100 minutes for the immediate-release form, against roughly 2 minutes for native somatostatin
Sequence length	8 residues	8 residues
Molecular weight	1,096.3 Da	1,019.3 Da
Studied in	CLARINET randomized 204 patients with non-functioning enteropancreatic neuroendocrine tumours and showed progression-free survival not reached at 24 months against 18 months on placebo. Acromegaly trials show biochemical control comparable to octreotide LAR, with extended dosing intervals feasible in responders.	Decades of trials in acromegaly show biochemical control in roughly 55–65% of patients on depot therapy. PROMID randomized octreotide LAR in metastatic midgut neuroendocrine tumours and showed a near-tripling of time to progression, establishing an antiproliferative effect beyond symptom control.
Who should avoid it	Known hypersensitivity Caution in pre-existing gallbladder disease Caution in diabetes without a glucose monitoring plan Caution in bradycardia or conduction disease	Known hypersensitivity Caution in existing gallbladder disease Caution in uncontrolled diabetes without a monitoring plan Caution in significant bradycardia or conduction disease
Legal status	Prescription-only. A US generic has been available since 2021, though supply has been intermittent.	Prescription-only. Generic injectable forms are widely available; depot and oral forms are not.

Benefits — Lanreotide

Prolongs progression-free survival in GEP-NETs
CLARINET is the strongest antiproliferative evidence in the class, and it was conducted in non-functioning tumours where there is no symptom benefit to confound the result.
Biochemical control in acromegaly
Normalises IGF-1 in a majority of patients, comparable to octreotide LAR in head-to-head and indirect comparisons.
Controls carcinoid syndrome symptoms
Reduces flushing and diarrhoea, with fewer rescue doses of short-acting octreotide needed in the ELECT trial.
Practical to administer at home
A prefilled deep subcutaneous injection with no reconstitution, which patients or partners are trained to give. Over a treatment course lasting years, this is not a trivial advantage.
Dosing interval can be extended in responders
Well-controlled patients are often maintained at 6 or 8 weeks rather than 4, reducing burden and cost.

Benefits — Octreotide

Biochemical control in acromegaly
Normalises IGF-1 and growth hormone in the majority of patients, and shrinks tumours in a substantial minority. First-line medical therapy when surgery is not curative.
Controls carcinoid syndrome
Reliably reduces flushing and secretory diarrhoea, which is often the dominant symptom burden in these tumours.
Slows tumour progression in midgut NETs
PROMID showed median time to progression extended from 6 to 14.3 months — an antiproliferative effect, not just symptom relief.
Reduces bleeding in oesophageal varices
Lowers splanchnic blood flow and portal pressure. Widely used acutely alongside endoscopic therapy.
Reduces output from high-output fistulas
Slows secretion and transit. Evidence is modest and mostly on fistula closure time rather than mortality.

Risks & cons — Lanreotide

Gallstones and biliary sludge
The same class effect as octreotide, developing in a substantial proportion on long-term therapy. Usually asymptomatic, occasionally requiring surgery.
Glucose dysregulation
Suppression of both insulin and glucagon moves glucose unpredictably; hyperglycaemia is more commonly reported than hypoglycaemia.
Injection site reactions and nodules
More prominent than with intramuscular depots because the drug sits in subcutaneous tissue. Site rotation and correct deep technique matter.
Gastrointestinal effects
Diarrhoea, abdominal pain and flatulence are common early and usually attenuate.
Bradycardia
A class effect, relevant alongside other rate-limiting drugs.

Risks & cons — Octreotide

Gallstones and biliary sludge
The characteristic complication, developing in a large minority on long-term therapy because gallbladder contractility is suppressed. Most are silent; some need cholecystectomy.
Disturbed glucose control in both directions
Suppresses insulin and glucagon together, so glucose can rise or fall depending on the patient. Diabetic regimens frequently need adjusting.
Gastrointestinal effects on starting
Cramping, bloating, nausea, loose or fatty stools. Usually settles over the first weeks but is a common reason for early discontinuation.
Bradycardia and conduction effects
Sinus bradycardia and conduction abnormalities occur, relevant in patients already on rate-limiting drugs.
Fat-soluble vitamin malabsorption
Follows from suppressed pancreatic exocrine secretion and steatorrhoea during long-term use.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.